Medicinova (MNOV) EBT Margin (2012 - 2025)

Medicinova's (MNOV) quarterly EBT Margin came in at 1841.01% in Q4 2025, up 29.37% on a QoQ basis from 2606.72% in Q3 2025.

Medicinova (MNOV) EBT Margin (2012 - 2025) Analysis & Trends

Medicinova (MNOV) has 5 years of EBT Margin data on file, last reported at 1841.01% in Q4 2025.

On a quarterly basis, EBT Margin changed N/A year-over-year to 1841.01% in Q4 2025; TTM through Dec 2025 was 3142.14%, a N/A change from a year earlier, with the FY2025 full-year figure at 2927.32%, changed N/A from the prior year.
EBT Margin for Q4 2025 stood at 1841.01%, up from 2606.72% in the prior quarter.
Over the last five years, EBT Margin for MNOV reached as high as 5.66% in Q1 2021 and fell as low as 12464.77% in Q3 2021.
Historically, EBT Margin has averaged 3291.35% across 3 years, with a median of 2223.86% in 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	17.13%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	41.95%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	23.05%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	34.77%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Medicinova	64.48 Mn	64.48 Mn	4,754.00	-1,841.01%

Download Data